最新ニュース Teladoc Health (NYSE:TDOC) 株価情報

Teladoc Health

Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

Equities

News

Markets

ETFs

$BTC

ABSI

ARKW

COIN

ROKU

TDOC

VERV

月曜日、Cathie Wood率いるArk Investが一連の大きな取引を行い、その中で最も注目されたのがCoinbase Global Inc.（コインベース）（NASDAQ:COIN）だった。これは、特に暗号通貨市場にとっては不穏な状況の中で行われた取引だ。今回のCOIN売買

アークインベストメント　コインベース株を売却

Teladoc Health Inc

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has risen 3.62% since its last report. The company recently reported that it has 23.53 million shares sold short, which is 17.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737060311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.32%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Teladoc Health's Recent Short Interest

Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are trading higher premarket on Tuesday. On Monday, the company disclosed a partnership with Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to broaden access to its chronic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42964279/teladoc-health-joins-amazons-health-benefits-connector-for-cardiometabolic-programs" rel="noreferrer noopener">condition management programs</a>.
Teladoc Health's chronic condition programs serve over 1 million active enrollees, utilizing connected devices, data-driven personalization, and expert coaching to promote lasting behavior changes and improve cardiometabolic health outcomes.
The company supports over 1 million enrollees in its chronic condition programs, using connected devices, personalized data, and expert coaching to improve cardiometabolic health.
Eligible Amazon customers can now discover and enroll in Teladoc's programs for diabetes, hypertension, pre-diabetes, and weight management through Amazon's Health Benefits Connector, previously known as Health Condition Programs.
Notably, over half of U.S. adults have a chronic condition, yet many face barriers to accessing digital health programs, the company said in the press release. Nearly 25% are unaware of their full health plan benefits.
Amazon's Health Benefits Connector addresses this by highlighting eligible benefits during product searches. Teladoc Health's participation reflects a joint effort to prioritize consumer-centric healthcare solutions.
Investors can gain exposure to the stock via KraneShares Trust KraneShares Man Buyout Beta Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUYO#NYSE">BUYO</a>).
<h2 class="wp-block-heading">Teladoc Health Stock Prediction for 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Teladoc Health, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Teladoc Health, the 200-day moving average sits at $10.07, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $9.7. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: TDOC shares are up 7.94% at $10.47 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/42362891/2-telehealth-stocks-that-could-gain-from-trumps-new-fda-pick" target="_blank" rel="noreferrer noopener">2 Telehealth Stocks That Could Gain from Trump's New FDA Pick</a></li>
</ul>
Photo: courtesy of Teladoc.

Mid Cap

Contracts

Movers

Tech

AMZN

KraneShares Trust KraneShares Man Buyout Beta Index ETF

BUYO

Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare

General

Teladoc Health shares are trading higher after the company joined Amazon's Health Benefits Connector for its cardiometabolic programs.

Reported Earlier, Teladoc Health Expands Chronic Condition Program Enrollment Through Partnership With Amazon

Telehealth companies including Hims &amp; Hers, Sesame and Noom have flocked to Facebook and Instagram to promote their booming weight loss drugs.
But pressure from regulators concerned about consumers' health data privacy has prompted Meta Platforms to limit how advertisers target users with health-related ads, starting this month. That is upending weight loss campaigns in the middle of the New Year's resolution marketing season. And more broadly, marketers are scrambling to figure out exactly what kind of weight loss and other health-related products are affected, and trying out workarounds for the new rules.
<a href="https://www.theinformation.com/articles/meta-ad-changes-threaten-telehealths-weight-loss-boom" title="https://www.theinformation.com/articles/meta-ad-changes-threaten-telehealths-weight-loss-boom">https://www.theinformation.com/articles/meta-ad-changes-threaten-telehealths-weight-loss-boom</a>
&nbsp;
&nbsp;
&nbsp;
&nbsp;

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

'Meta Ad Changes Threaten Telehealth's Weight Loss Boom' - The Information

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 13.48% since its last report. The company recently reported that it has 22.71 million shares sold short, which is 17.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735671624_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Teladoc Health's Recent Short Interest

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.0, a high estimate of $14.00, and a low estimate of $8.00. This current average reflects an increase of 18.41% from the previous average price target of $9.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1733320944_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Teladoc Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.21%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Teladoc Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Unveiling 8 Analyst Insights On Teladoc Health

Piper Sandler analyst Jessica Tassan reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $11 to $13.

Price Target

Reiteration

Piper Sandler Reiterates Overweight on Teladoc Health, Raises Price Target to $13

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 25.69 million shares sold short, which is 19.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732905912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Teladoc Health?

Teladoc Health Launches New AI-Capabilities To Enhance Virtual Sitter Solution To Improve Patient Safety

Goldman Sachs analyst David Roman initiates coverage on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy rating and announces Price Target of $14.

Initiation

Goldman Sachs Initiates Coverage On Teladoc Health with Buy Rating, Announces Price Target of $14

Deutsche Bank analyst George Hill maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $10 to $12.

Deutsche Bank Maintains Hold on Teladoc Health, Raises Price Target to $12

Barclays analyst Steve Valiquette maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $10 to $12.

Barclays Maintains Overweight on Teladoc Health, Raises Price Target to $12

TD Cowen analyst Charles Rhyee maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.

TD Cowen Maintains Hold on Teladoc Health, Lowers Price Target to $8

WIIM

Teladoc Health shares are trading higher after the company reported Q3 earnings and sales that beat analyst estimates.

Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are moving higher in extended trading Wednesday after the company reported financial results for the third quarter that <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results">topped analyst expectations</a>.
<ul>
<li>Q3 Revenue: $640.51 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $631.16 million</li>
</ul>
<ul>
<li>Q3 EPS: Loss of 19 cents, versus estimates for a loss of 27 cents</li>
</ul>
Total revenue was down 3% on a year-over-year basis. Integrated Care segment revenue was up 2% year-over-year, while BetterHelp segment revenue declined 10% year-over-year. U.S. revenue fell 6% year-over-year, while International revenue grew 15%.
Cash flow from operations totaled $110.2 million in the third quarter. The company said it generated $79 million in free cash flow during the quarter.
&#8220;As we close out 2024, we are moving with urgency and making changes to more effectively leverage our leadership position in the complex and dynamic markets we serve. There is more work ahead of us, and 2025 will be an important repositioning year. Our focus remains on delivering consistent performance and driving long-term shareholder value,&#8221; said Chuck Divita, CEO of Teladoc Health.
Guidance: Teladoc expects fourth-quarter Integrated Care segment revenue to be flat to up 2.5% in the fourth quarter. The company expects full-year Integrated Care segment revenue to grow in the low single digits to mid-single digits.
TDOC Price Action: <a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were up 9.26 % in after-hours, trading at $9.68 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">Meta Platforms Q3 Earnings: Revenue Beat, EPS Beat, Daily Actives Up 5%, &#8216;Strong Momentum&#8217; In AI</a>
Photo: Courtesy of Teladoc.

Earnings

Guidance

Health Care

After-Hours Center

Teladoc Health Q3 Earnings: Revenue Beat, EPS Beat, Shares Jump 10%

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. The company reported quarterly sales of $640.508 million which beat the analyst consensus estimate of $631.160 million by 1.48 percent. This is a 2.99 percent decrease over sales of $660.238 million the same period last year.

Earnings Beats

Teladoc Health Q3 2024 GAAP EPS $(0.19) Beats $(0.27) Estimate, Sales $640.508M Beat $631.160M Estimate

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-10-30. Here's what investors need to know before the announcement.
Analysts estimate that Teladoc Health will report an earnings per share (EPS) of $-0.27. 
Investors in Teladoc Health are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 8.91% drop in the share price on the following day.
Here's a look at Teladoc Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.34</td>
<td>-0.46</td>
<td>-0.21</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.49</td>
<td>-0.17</td>
<td>-0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>-24.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730224943_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Teladoc Health were trading at $9.18 as of October 28. Over the last 52-week period, shares are down 46.1%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Observations about Teladoc Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.
The consensus rating for Teladoc Health is Neutral, based on 15 analyst ratings. With an average one-year price target of $10.47, there's a potential 14.05% upside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Certara, Schrodinger and Phreesia, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Certara is maintaining an Neutral status according to analysts, with an average 1-year price target of $16.0, indicating a potential 74.29% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schrodinger, with an average 1-year price target of $27.5, suggesting a potential 199.56% upside.</li>
<li>For Phreesia, analysts project an Buy trajectory, with an average 1-year price target of $29.4, indicating a potential 220.26% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Certara, Schrodinger and Phreesia, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-1.53%</td>
<td>$454.38M</td>
<td>-44.19%</td>
</tr>
<tr>
<td>Certara</td>
<td>Neutral</td>
<td>3.17%</td>
<td>$53.50M</td>
<td>-1.20%</td>
</tr>
<tr>
<td>Schrodinger</td>
<td>Neutral</td>
<td>34.51%</td>
<td>$31.34M</td>
<td>-10.94%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's performance is below average compared to its peers in terms of Revenue Growth and Gross Profit, but it is relatively better in terms of Return on Equity.
<h3>Get to Know Teladoc Health Better</h3>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Financial Insights: Teladoc Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Teladoc Health's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -1.53% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -130.39%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -44.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.06, Teladoc Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/TDOC/earnings">To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Teladoc Health's Earnings

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

CDNA

IRMD

OMCL

TCMD

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

RBC Capital analyst Sean Dodge maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and raises the price target from $9 to $10.

RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $10

Teladoc rises on collaboration news with Amazon

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Teladoc (TDOC – Research Report). The company's share...

Truist Financial Keeps Their Hold Rating on Teladoc (TDOC)

Biggest stock movers Tuesday: HEES, KBH, CHGG, and more

Unusual total active option classes on open include: Applied Digital Corp (APLD), Rocket Companies (RKT), Trump Media (DJT), Teladoc (TDOC), B Rile...

Unusually active option classes on open January 14th

Biggest stock movers Tuesday: LLY, HEES, KBH, CHGG, and more

Teladoc Health, Inc. (TDOC) JPMorgan 43rd Annual Healthcare Conference (Transcript)

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Eli Lilly (LLY) cut its FY24 rev...

Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz

Discover the top stock picks for today's risk-on market, driven by light PPI data and anticipation of CPI. This article provides a macro review, detailed analyses of key trades, and swing trade opportunities, including KTOS, NBIS, ROOT, and more.

Light PPI Sparks Optimism: Today's Must-Watch Stocks

Teladoc Health has partnered with Amazon to improve healthcare access through streamlined enrollment.

TDOC Stock Gains As Amazon Partnership Aims To Enhance Firm's U.S. Reach

The number of Americans receiving psychotherapy has increased 30% during the pandemic, but research shows the shift to teletherapy has exacerbated ...

Study shows online therapy boom mostly benefited priviledged groups, NYT says

ACMR

AEHR

ALUR

AMWL

ANGI

APLD

ARBE

CART

CHGG

DOCS

GOOG

GOOGL

HEES

HOOD

ILMN

KTOS

KULR

MIND

NBIS

OPFI

PDYN

QTRX

QUIK

RGTI

RILY

ROOT

TALK

TRUG

VALE

XPEV

Press Releases

Teladoc Health Reports Third Quarter 2024 Results

Teladoc Health Announces Employee Inducement Awards Under NYSE Rule 303A.08

Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential

Teladoc Health to Participate in Upcoming Investor Conference

Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

Opinion

AI Healthcare Innovations: How They're Shaping the Future for Patients and Investors

Teladoc Health Joins Amazon's Health Benefits Connector for Cardiometabolic Programs

How HealthCare Industry is Leveraging Artificial Intelligence to Revolutionize Diagnostics and Early Disease Detection

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

AVAI

BFLY

CLOV

HWAIF

RHHBY

RXRX

TSX:AIDX

TSX:WELL

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Veeva Systems

Waystar Holding

Piper Sandler

Goldman Sachs

Deutsche Bank

Barclays

TD Cowen

月曜日、Cathie Wood率いるArk Investが一連の大きな取引を行い、その中で最も注目されたのがCoinbase Global Inc.（コインベース）（NASDAQ:COIN）だった。これは、特に暗号通貨市場にとっては不穏な状況の中で行われた取引だ。
今回のCOIN売買
Ark Investのこの日最も顕著な取引は、最大手暗号通貨取引プラットフォームであるCoinbaseとのものだ。この取引は、ビットコイン（CRYPTO:BTC）の価格が6万2,000ドルを割り込んだというタイミングで行われたもので、<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39459091/coinbase-shares-tumble-with-bitcoin-whats-going-on-with-the-stock">暗号通貨市場がかなりの揺れを体験している</a>状況でのものだ。このビットコイン価格の下落はCoinbase株に直接的な影響を与え、同社の株価も月曜日、前週末の取引で下げてしまった。
月曜日の取引の最後にCoinbase株は212.31ドルで推移していた。同社は、 ARK Next Generation Internet ETF（NYSE:ARKW）を通じて3,341株のCoinbase株を売却。この取引は709,327ドルに相当する。
その他の注目すべき取引
関連記事：『ドージコインキラー』Shiba Inu、悪化-短期的な将来の見通しについて示す主要指標<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448955/dogecoin-killer-shiba-inu-falters-here-is-what-these-key-indicators-reveal-about-its-short?itm_source=parsely-api" target="_blank" rel="noopener noreferrer">リンク</a> 
<ul>
<li>Teladoc Health Inc（NYSE:TDOC）：ARKG ETF から54,256株、ARKK ETFから61,606株の売却。</li>
<li>Absci Corp（NASDAQ:ABSI）：ARKG ETF に43,936株の取得。</li>
<li>Verve Therapeutics Inc（NASDAQ:VERV）：ARKG ETF から10,570株、ARKK ETF から50,971株の売却。</li>
<li>Roku Inc（NASDAQ:ROKU）：ARKK ETF に32,989株の取得。</li>
</ul>
次の記事を読む: ビットコイン、イーサリアム、ドージコインが投資家の懸念で下落- 60,000ドルまでの激しい下げ<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448829/bitcoin-ethereum-dogecoin-fall-on-investor-worries-analyst-warns-of-king-cryptos-dip-below?itm_source=parsely-api" target="_blank" rel="noopener noreferrer">リンク</a> 
本記事は <a href="https://www.benzinga.com/author/benzinga-neuro"> Benzinga Neuro </a>によって生成され、<a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener noreferrer"> Shivdeep Dhaliwal</a>によって編集されました。

Comments

Teladoc Health

ニュース

最新ニュース Teladoc Health (NYSE:TDOC) 株価情報

火曜日, 6 25, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル